Navigation Links
Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors
Date:5/30/2008

ectives of the Phase 1 open-label, dose-escalation study are to evaluate the safety and tolerability of HGS1029 as monotherapy in patients with advanced solid tumors, and to select a recommended dose for Phase 2 studies. Secondary objectives include documenting possible anti-tumor activity and determining HGS1029's pharmacokinetic profile. HGS1029 will be administered as a 15-minute infusion once weekly for 3 consecutive weeks followed by a week off. Up to 40 patients will be treated in the study, with 15-20 patients treated in the dose-escalation phase.

About the HGS Oncology Portfolio

HGS is investing strategically to expand and advance its oncology portfolio around its leading expertise in the apoptosis pathway. HGS has initiated new chemotherapy combination trials of HGS-ETR1 (mapatumumab), added the new opportunity to develop and commercialize HGS1029 and other IAP inhibitors, and reacquired the rights to its TRAIL receptor antibodies. HGS-ETR1, the Company's antibody to TRAIL receptor 1, is the most advanced of any product in development that targets the TRAIL apoptosis pathway.

About Human Genome Sciences

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs.

The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax, cancer and other immune-mediated diseases. The Company's primary focus is rapid progress toward the commercialization of its two key lead drugs, Albuferon(R) for hepatitis C and LymphoStat-B(R) (belimumab) for lupus. Phase 3 clinical trials of both drugs are ongoing.

ABthrax(TM) (raxibacumab) is in late-stage development for the treatment of inhalation anthrax, and the Company is on track to begin the delivery in fall 2008 of 20,000 doses of ABthrax to the Strategic National Stockpile under a contract entered into with the U.S. Government in June 2006. Other HGS drugs in clinical devel
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... Oct. 17, 2014 With the recent ... function has come across several challenges in creating ... managing globalization.  The Medical ... dedicated to providing benchmarking and best practices across ... is a service composed of three stages: 1) ...
(Date:10/17/2014)... Oct. 17, 2014  Hanger, Inc. (NYSE: ... its results of operations for the quarter ended September ... market closes.  A conference call to discuss these results ... Friday, November 7, 2014. Those wishing to participate should ... November 14, 2014 by dialing 1-855-859-2056 and referencing Conference ...
(Date:10/17/2014)... UBM Medica US announces that Neurology ... information resource for neurologists and other healthcare providers, features special ... , with discussions of the latest developments in approaches to ... Parkinson disease , more than the total of those who ... disease. Diagnosis can be difficult because there are no confirmatory ...
Breaking Medicine Technology:Early Key Findings from the Medical Affairs Consortium Research 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 3
... Md., May 9, 2011 /PRNewswire-USNewswire/ – CoMeD – On ... State Senator filed an amendment to regulate vaccines containing ... illegal to buy, sell, manufacture, deliver, import, administer or ... of organic or inorganic mercury per milliliter for children ...
... BUFFALO, N.Y., May 9, 2011 Kinex Pharmaceuticals, LLC announced ... Chief Executive Officer, has decided to step aside as CEO. ... see Kinex Pharmaceuticals evolve from a start-up biotechnology company with ... of two compounds in pre-IND to phase 2 developments. The ...
Cached Medicine Technology:Florida Legislature Refuses to Limit Mercury in Vaccines 2Florida Legislature Refuses to Limit Mercury in Vaccines 3The Board of Directors of Kinex Pharmaceuticals Appoints Dr. Allen Barnett as President Emeritus and Dr. Johnson Lau as Chief Executive Officer 2The Board of Directors of Kinex Pharmaceuticals Appoints Dr. Allen Barnett as President Emeritus and Dr. Johnson Lau as Chief Executive Officer 3
(Date:10/20/2014)... (PRWEB) October 20, 2014 With a ... Gov. Charlie Crist made a brief fundraising stop at ... on Thursday. , Fresh from a debate last night ... take the stage for the first seven minutes because ... former governor described the incident in one word: "weird." ...
(Date:10/20/2014)... Columbus, OH (PRWEB) October 20, 2014 ... joined Specialists in Obstetrics & Gynecology of Columbus, Inc., ... specialized women’s healthcare services to more than 100,000 patients ... care though all ages and stages of a women’s ... office locations in Westerville and Dublin. , ...
(Date:10/20/2014)... JZ Fitness, an independently operated wellness brand ... authorship, international lecturing and community wellness, created by Jenn ... of the JZ Fitness nutrition app, available on iTunes. ... of individuals on nutrition, Jenn Zerling (“JZ”) has developed ... calorie counting or cumbersome food logging. , ...
(Date:10/20/2014)... Myoderm announced today ... of their CentralSource service. Matthew will ... turnkey drug sourcing, distribution, and management service for ... years of industry experience, in both business development ... of their international success to help clients manage ...
(Date:10/20/2014)... Columbus, OH (PRWEB) October 20, 2014 National ... Ohio Chapter of the American Academy of Pediatrics (Ohio AAP, ... Administration (NHTSA) in encouraging parents of teen drivers to talk ... hit the road. , Motor vehicle crashes are the leading ... 2,055 teen drivers involved in fatal crashes, and 859 (42%) ...
Breaking Medicine News(10 mins):Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3Health News:JZ Fitness Nutrition App Launches on iTunes 2Health News:JZ Fitness Nutrition App Launches on iTunes 3Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2
... New Dynamics of Ageing Programme (NDA), a collaboration between ... and Humanities Research Council, the Biotechnology and Biological Sciences ... the Economic and Social Research Council and the Medical ... applications to be funded under the programme. , ...
... Oct. 18 ReBuilder,Medical Technologies, Inc. (Pink ... by world-renowned medical device inventor David B.,Phillips, ... service organization and facilitation. (Logo: ... when many companies are outsourcing customer service ...
... Cost of Prescription Drugs, WASHINGTON, Oct. 18 ... following statement in response to,today,s House Judiciary Committee ... independent pharmacists sweeping antitrust,exemptions:, "This bill couldn,t ... and,consumers alike. As most everyone is searching for ...
... UK awarding body associated with hairdressing and beauty therapy ... a major UK Centre for Burns Research based at ... of its kind by The Vocational Training Charitable Trust ... pioneering research programme soon to start in South Wales. ...
... Children Under 5 in Madagascar to Sleep Under Bed ... More and,Sumitomo Chemical have teamed up to contribute to ... Madagascar between October 22-29. Led by the Malagasy ... six months to five years old receives a bed ...
... The Bayer Foundation,announced today it has awarded ... of Chemical & Biomolecular Engineering (UH CHBE) to,establish ... which is competitive with other prestigious fellowships,from the ... over a,three-year period to a graduate student pursuing ...
Cached Medicine News:Health News:Research for a better old age 2Health News:Research for a better old age 3Health News:ReBuilder Medical Technologies, Inc. Hires Nurses Exclusively to Provide Customer Support 2Health News:ReBuilder Medical Technologies, Inc. Hires Nurses Exclusively to Provide Customer Support 3Health News:£1 million donation for burns research in Wales 2Health News:Malaria No More and Sumitomo Chemical Help Protect 1.4 Million Kids from Malaria 2Health News:Malaria No More and Sumitomo Chemical Help Protect 1.4 Million Kids from Malaria 3Health News:Bayer Foundation Grant Creates Graduate Engineering Fellowship at University of Houston 2Health News:Bayer Foundation Grant Creates Graduate Engineering Fellowship at University of Houston 3